Brought to you by 
Baxter buys Aes103 sickle cell program through AesRx takeover
26 Aug 2020
Executive Summary
As it prepares to spin off its biopharma business next year, Baxter International Inc. made another acquisition to build up hemophilia assets, this time buying closely held AesRx LLC (orphan diseases). The transaction included an up-front payment plus development, regulatory, and commercial earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter buys Aes103 sickle cell program through AesRx takeover
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice